Online inquiry

IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4089MR)

This product GTTS-WQ4089MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4089MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11580MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ2717MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ7586MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ7211MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ4737MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ18MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ2570MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ3962MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW